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INTRODUCTION 
 
Cerebral amyloid angiopathy (CAA) is one of the leading 
causes for spontaneous lobar intracerebral hemorrhage 
(ICH) in the elderly. Patients with CAA show 
substantially higher risks of recurrent ICH at a rate of 6.9 - 
10% per year [1–3] compared with deep ICH of about 3% 
per year [4], leading to subsequent disability and 
mortality. So far, the prediction of ICH recurrence and 
disease severity for CAA mostly depends on brain 
imaging features, including the number of previous ICH 
and cerebral microbleeds (CMBs), posterior white matter 
hyperintensities (WMH) [1, 5] and cortical superficial 
siderosis (cSS), among which cSS is most clinically 
relevant [2, 3]. However CAA-related MRI features 
represent vascular endpoints of CAA rather than 
neurodegenerative processes that might influence disease 
progression and recurrence risk [6]. 
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ABSTRACT 
 
Predicting recurrent intracerebral hemorrhage (ICH) related to cerebral amyloid angiopathy (CAA) currently 
relies on brain images. We aimed to investigate whether blood neurodegenerative biomarkers predict disease 
severity and ICH recurrence in CAA. We recruited 68 first probable CAA-ICH cases from a Chinese prospective 
cohort, and 95 controls. We used the single-molecule array to measure acute phase blood amyloid-40, amyloid-
42, total tau and neurofilament light chain (NfL). We used multivariable Cox regression models to assess the 
association between blood biomarkers and CAA-ICH recurrence, and used the concordance (c-) index to assess 
prediction models. Blood amyloid-42/40, total tau, and NfL levels changed in CAA-ICH cases than controls. 
During a median follow-up of 2.4 years, NfL was associated with CAA-ICH recurrence (adjusted hazard ratio 
2.14, 95% CI 1.57-2.93) independent of MRI burden of small vessel disease (SVD). The performance of a model 
to predict CAA-ICH recurrence using MRI burden of SVD alone (c-index 0.77) increased with the addition of NfL 
(c-index 0.88, 95% CI 0.73-1.00, p=0.019). Further, NfL was associated with baseline ICH volume, NIHSS and 6-
month mRS score. Blood NfL is associated with severity and prognosis of CAA-ICH and is a promising addition to 
MRI burden of SVD to predict CAA-ICH recurrence. 
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Growing evidence suggests the interplay between 
vascular damage and neurodegeneration in Alzheimer’s 
disease and CAA [7, 8]. Molecular biomarkers, 
especially blood-based, may provide an easy approach 
in directly measuring the underlying processes[9, 10]. 
However, the utilities of circulating biomarkers for 
CAA are still underexplored except for the diagnostic 
value of APOE genotype, β-amyloid (Aβ) 42 and Aβ40. 
APOE ε4 possession has strong association with CAA 
pathology and helps diagnose CAA-ICH [11], but may 
not be generally available worldwide. The decreased 
cerebrospinal fluid Aβ42, Aβ40 and total tau serve as 
biomarkers for distinguishing CAA from controls [6], 
while the diagnostic utilities of blood Aβ and tau are 
still controversial [12, 13]. As a structural scaffolding 
protein in the brain, neurofilament light chain (NfL) is 
highly specific for axonal injury and eventual neuronal 
cell death and shows prognostic values in various 
central nervous system diseases [14], which has not 
been well studied in CAA. Therefore, we hypothesized 
that neurodegenerative biomarkers might predict further 
vascular damage. We aimed to examine whether blood 
biomarkers of Aβ42, Aβ40, total tau and NfL in CAA 
indicate disease severity and predict prognosis.  
 
RESULTS 
 
A total of 144 cases with primary lobar ICH were 
admitted in two independent hospitals in China during 
the study period, and finally 68 cases with first-ever 
probable CAA-ICH (Figure 1) and 95 healthy elder 
controls were included in the study. 
 
Study population 
 
The demographic data, clinical manifestations and 
imaging characteristics of healthy controls, and cases 
with CAA-ICH overall and according to lobar ICH 
recurrence were shown in Table 1. For cases with CAA, 
the mean ± standard deviation (SD) age was 70.1±9.1 
years and 73.5% were males. During a median 
(interquartile range [IQR]) follow-up of 2.4 (1.3-4.0) 
years, 19 (27.9%) patients had recurrent lobar ICH 
without deep ICH. The ICH recurrence was associated 
with older age, higher degree of periventricular spaces 
in the centrum semiovale (CSO-PVS) and heavier total 
MRI burden of small vessel disease (SVD), but not 
lobar CMBs count, cSS presence or extent, or WMH 
Fazekas score in univariable Cox regression analyses in 
our cohort (Table 2). 
 
Comparisons of blood biomarkers between CAA-
ICH cases and controls  
 
Compared to healthy controls, cases with CAA-ICH 
showed elevated NfL (median [IQR], 14.3 [10.3-20.4] 
vs. 70.1 [22.3-320.0] pg/ml, p<0.001) and total tau 
(median [IQR], 2.9 [2.2-4.1] vs. 3.7 [2.6-4.8] pg/ml, 
p=0.011) levels, and decreased Aβ42/Aβ40 (mean ± 
SD, 0.047±0.015 vs. 0.043±0.006, p=0.035) levels, 
 
 
 
Figure 1. Study flow chart. Abbreviations: ICH, intracerebral hemorrhage; CAA, cerebral amyloid angiopathy. 
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Table 1. Demographic, clinical and imaging data and blood biomarkers of healthy controls and cases with probable 
CAA-ICH (subdivided according to ICH recurrence). 
Variables Healthy controls 
First-ever probable 
CAA-ICH 
P 
Value 
CAA with lobar ICH 
recurrence 
 (n=95) (n=68)  No (n=49) Yes (n=19) 
Age of onset, y 69.0 ± 8.3 70.1 ± 9.1 0.43 68.5 ± 9.5 74.1 ± 6.9 
Sex, male 63 (66.3) 50 (73.5) 0.33 35 (71.4) 15 (78.9) 
Major clinical presentation 
Cognitive decline 
/behavior changes 
NA 11 (16.2) 
NA 
7 (14.3) 4 (21.1) 
Focal neurological 
deficits 
NA 42 (61.8) 31 (63.3) 11 (57.9) 
Headache NA 8 (11.8) 6 (12.2) 2 (10.5) 
Transient focal 
neurological 
episodes 
NA 2 (2.9) 2 (4.1) 0 
Unconsciousness NA 5 (7.4) 3 (6.1) 2 (10.5) 
Past history 
Hypertension 38 (40.0) 48 (70.6) <0.001 36 (73.5) 12 (63.2) 
Diabetes mellitus 14 (14.7) 15 (22.1) 0.23 11 (22.4) 4 (21.1) 
Dyslipidemia 17 (17.9) 7 (10.3) 0.18 7 (14.3) 0 
Pre-existing 
dementia 
0 10 (14.7) <0.001 4 (8.2) 6 (31.6) 
Smoking 32 (33.7) 16 (23.5) 0.16 11 (22.4) 5 (26.3) 
Antiplatelet drug use 10 (10.5) 21 (30.9) 0.001 16 (32.7) 5 (26.3) 
Anticoagulant drug 
use 
1 (1.1) 4 (5.9) 0.16 3 (6.1) 1 (5.3) 
Brain MRI findings 
Lobar CMBs count 0 (0-0) 13.0 (5-64) <0.001 22 (5-73) 10 (5-43) 
cSS presence 2 (2.1) 26 (38.2) <0.001 16 (32.7) 10 (52.6) 
cSS extent 0 (0-0) 0 (0-1) <0.001 0 (0-1) 1 (0-2) 
WMH Fazekas score 2 (2-3) 4 (4-6) <0.001 4 (4-5) 4 (4-6) 
CSO-PVS 2 (1-2) 2 (2-3) 0.001 2 (2-2) 3 (2-3) 
Lacune 0 (0-0) 1 (0-2) <0.001 1 (0-2) 0 (0-1) 
Total MRI burden of 
SVD 
1 (0-2) 3.5 (3-4) <0.001 3 (3-4) 4 (4-5) 
Blood biomarkers 
Neurofilament light 
chain, pg/mL 
14.3(10.3-20.4) 
70.1 
(22.3-320.0) 
<0.001 
36.6 
(19.9-106.0) 
368.6 
(123.3-790.9) 
β-amyloid 40, pg/mL 229.3 ± 61.9 243.3 ± 71.9 0.19 244.9 ± 57.5 239.1 ± 101.9 
β-amyloid 42, pg/mL 10.1 ± 2.4 10.2 ± 3.0 0.79 10.5 ± 2.7 9.5 ± 3.6 
β-amyloid 42/40 0.047 ± 0.015 0.043 ± 0.006 0.035 0.043 ± 0.007 0.042 ± 0.005 
Total tau, pg/mL 2.9 (2.2-4.1) 3.7 (2.6-4.8) 0.011 3.7 (2.6-4.3) 4.4 (2.6-5.7) 
Abbreviations: CAA, cerebral amyloid angiopathy; ICH, intracerebral hemorrhage; CMBs, cerebral microbleeds; cSS, cerebral 
superficial siderosis; WMH, white matter hyperintensities; CSO-PVS, centrum semiovale perivascular space; SVD, small vessel 
disease.  
Data are shown as n (%) for categorical variables, mean ± SD for normally distributed continuous variables or median (interquartile 
range) for non-normally distributed continuous variables. 
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Table 2. Cox regression models for ICH recurrence after first-ever probable CAA-ICH. 
 Univariable analyses Multivariable analyses* 
Variables HR (95% CI) P Value HR (95% CI) P Value 
Clinical and imaging risk factors for CAA-ICH recurrence 
Age (per year increase) 1.06 (1.01–1.11) 0.032   
Sex (male vs. female) 0.79 (0.26–2.40) 0.67   
Pre-existing dementia (yes vs. no) 2.19 (0.81–5.90) 0.12   
Total MRI burden of SVD (per point increase) 1.77 (1.21–2.60) 0.003 1.77 (1.21–2.60) 0.003 
cSS presence (yes vs. no) 1.77 (0.72–4.39) 0.22   
Disseminated cSS (yes vs. no) 2.15 (0.83–5.56) 0.12   
Lobar CMBs count (per CMB increase) 0.99 (0.98–1.00) 0.17   
WMH Fazekas score (per point increase) 0.98 (0.70–1.38) 0.90   
CSO-PVS (per point increase) 1.85 (1.08–3.18) 0.026   
Blood biomarkers for CAA-ICH recurrence† 
Total MRI burden of SVD (per point increase) 1.77 (1.21–2.60) 0.003 2.31 (1.39–3.83) 0.001 
Neurofilament light chain 2.03 (1.5 –2.74) <0.001 2.14 (1.57–2.93) <0.001 
β-amyloid 40 0.23 (0.04–1.41) 0.11   
β-amyloid 42 0.12 (0.02–0.64) 0.013   
β-amyloid 42/40 0.22 (0.01–6.20) 0.38   
Total tau 1.71 (0.71–4.13) 0.24   
Abbreviations: CAA, cerebral amyloid angiopathy; ICH, intracerebral hemorrhage; HR, hazard ratio; SVD, small vessel disease; 
CMBs, cerebral microbleeds; cSS, cerebral superficial siderosis; WMH, white matter hyperintensities CSO-PVS, centrum 
semiovale perivascular space. 
*The multivariable models included only the covariables for which HRs were provided. 
†All variables of blood biomarkers were continuous and Log-transformed. 
 
with no differences in Aβ42 (mean ± SD, 10.1±2.4 vs. 
10.2±3.0 pg/mL, p=0.79) or Aβ40 (mean ± SD, 
229.3±61.9 vs. 243.3±71.9 pg/mL, p=0.19) alone  
(Table 1). 
 
Clinical model for ICH recurrence prediction in CAA 
 
All the potential clinical and imaging risk factors for 
recurrent ICH were assessed in our cohort. Total MRI 
burden of SVD predicted risk of ICH recurrence best 
(adjusted hazard ratio [HR] 1.77, 95% confidence 
intervals [CI] 1.21-2.60, P=0.003), none of other clinical 
or imaging markers contributing with additional 
predictive value (Table 2). Model 1 of total MRI burden 
of SVD was generated with Harrell’s concordance index 
(c-index) of 0.77 (95% CI, 0.62-0.92) (Figure 2A). 
 
Blood biomarkers for ICH recurrence prediction in 
CAA  
 
Then, blood biomarkers of Aβ42 and NfL were 
associated with CAA-ICH recurrence in univariable 
analyses. Since there were only 19 ICH recurrences in 
our cohort, a maximum of two predictors were allowed 
in the multivariable model. Multivariable Cox 
regression analyses with forward selection 
demonstrated that blood NfL was associated with 
CAA-ICH recurrence (adjusted HR 2.14, 95% CI 1.57-
2.93) independent of total MRI burden of SVD 
(adjusted HR 2.31, 95% CI 1.39-3.83) (Table 2). After 
adding NfL to the clinical model (Model 1), Model 2 
of total MRI burden of SVD and NfL showed c-index 
of 0.88 (95% CI, 0.73-1.00) with improvement 
compared to Model 1 (P =0.019) (Figure 2B). The 
calibration curve for probability of recurrent ICH from 
internal bootstrap validation demonstrated satisfactory 
agreement between actual and predicted probabilities 
(Figure 2A, 2B). 
 
When plotting the receiver operating characteristic 
(ROC) curve, the area under the curve of blood NfL for 
predicting ICH recurrence in cases with CAA-ICH was 
0.84 (95% CI 0.74-0.93, p<0.001, Figure 3A). In 
Kaplan–Meier analysis, cases with blood NfL level 
above the highest tertile (>320.0 pg/mL) had shorter 
ICH-free survival time than those with NfL below 320.0 
pg/mL (log-rank test, P <0.001, Figure 3B). 
 
Association of NfL and ICH volume, baseline NIHSS 
and clinical outcome 
 
Further, blood NfL level was well correlated with ICH 
lesion volume (adjusted coefficient 4.71, 95% CI 0.68-
8.73), baseline NIH Stroke Scale (NIHSS) score 
(adjusted odds ratio [OR] 1.68, 95% CI 1.22-2.31) and 
6-month modified Rankin scale (mRS) score (adjusted 
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OR 1.75, 95% CI 1.22-2.51) in multivariable analyses 
(Table 3).  
 
DISCUSSION 
 
In this study, we established a prospective cohort of cases 
diagnosed with first probable CAA-ICH in China, and 
explored SVD imaging markers and blood biomarkers of 
Aβ42, Aβ40, total tau and NfL for prediction of clinical 
outcomes in CAA. Blood biomarkers of Aβ42/40, total 
tau and NfL changed between CAA-ICH and controls. 
For predicting ICH recurrence in CAA, total MRI burden 
of SVD and NfL were the best clinical and blood 
biomarkers respectively. The performance of a model to 
predict CAA-ICH recurrence using MRI burden of SVD 
alone increased with the addition of NfL (c-index from 
0.77 to 0.88, p=0.019). NfL also correlated to disease 
severity and clinical outcomes in CAA. We demonstrated 
that blood NfL assist the prediction of ICH recurrence and 
clinical outcomes, as well as assessment of clinical 
severity in CAA. 
 
CAA occupies 14.6% in all subtypes of ICH in Chinese 
population [15], but to our knowledge no prospective 
Chinese CAA cohort with ICH recurrence has been 
reported. The rate of ICH recurrence in our study was 
27.9% after a median follow-up of 2.4 years, similar to 
that of Massachusetts General Hospital (MGH) cohort. 
Our study found that total MRI burden of SVD other 
than any single SVD marker, was the only imaging 
biomarker of recurrent CAA-ICH. This cumulative 
score exerted gross effects of SVD on brain[16]. 
 
 
 
Figure 2. Calibration curves of Model 1 (A: total MRI burden of SVD) and Model 2 (B: total MRI burden of SVD and blood NfL) for predicting 
CAA-ICH recurrence using internal bootstrap validation. Abbreviations: CAA, cerebral amyloid angiopathy; ICH, intracerebral hemorrhage; 
SVD, small vessel disease; NfL, neurofilament light chain. 
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Previous studies found that it was independently 
associated with CAA-related vasculopathic changes and  
symptomatic CAA-ICH in a neuropathologic cohort and 
predicted dementia conversion in CAA patients without 
ICH [16, 17]. It was also related to higher ICH 
recurrence risk in a large prospective cohort from 
MGH, but its effect was mainly from the disseminated 
cSS [2, 18]. Although cSS has been determined as the 
most important MRI prognostic factor of recurrent ICH 
in CAA from a meta-analysis [2], there are several 
different clinical features between all the reported and 
our cohorts. Different ethnic backgrounds of Asian and 
White people may lead to various pathophysiological 
processes for SVD, since Asian patients tend to have a 
higher prevalence of hypertension and overall SVD load 
[19, 20]. Patients with CAA in our cohort showed 
extremely higher CMBs burden but similar cSS severity 
compared to those in other reported cohorts, which 
indicated advanced bleeding-prone microangiopathy of 
our patients. Further, to exclude effects of previous ICH 
on imaging and blood markers, we only recruited 
patients with first onset of probable CAA-ICH. These  
 
 
 
Figure 3. (A) Receiver operating characteristic curve of blood NfL for predicting ICH recurrence in cases with CAA. (B) Kaplan–Meier curve 
showing the ICH-free survival probability in CAA-ICH cases with blood NfL above vs. below 320.0 pg/mL. Abbreviations: NfL, neurofilament 
light chain; CAA, cerebral amyloid angiopathy; ICH, intracerebral hemorrhage; AUC, area under the curve. 
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Table 3. The association between blood NfL level and ICH volume, baseline NIHSS and clinical outcome. 
Variables 
Unadjusted Multivariable adjusted 
Coefficient (95% CI) P Value Coefficient (95% CI) P Value Coefficient (95% CI) P Value 
Log NfL and ICH volume 5.95 (2.33–9.56) 0.002 5.76 (2.12–9.41)* 0.002 4.71 (0.68-8.73)† 0.023 
Variables OR (95% CI) P Value OR (95% CI) P Value OR (95% CI) P Value 
Log NfL and baseline NIHSS 
(per point increase) 
1.88 (1.37–2.58) <0.001 1.83 (1.34–2.52)* <0.001 1.68 (1.22-2.31)# 0.002 
Log NfL and 6-month mRS 
(per point increase) 
2.28 (1.63–3.18) <0.001 2.26 (1.61–3.17)* <0.001 1.75 (1.22-2.51)† 0.002 
Abbreviation: NfL, neurofilament light chain; ICH, intracerebral hemorrhage; OR, odds ratio; NIHSS, NIH stroke scale; mRS, 
modified Rankin scale. 
*Adjusted for total MRI burden of SVD. 
†Adjusted for age, baseline NIHSS and total MRI burden of SVD. 
#Adjusted for age, ICH volume and total MRI burden of SVD. 
 
might explain that total MRI burden of SVD instead of 
cSS was predictive of ICH recurrence in CAA in our 
cohort. 
 
Emerging data focus on the MRI signatures for CAA, 
while the utility of blood biomarkers in CAA is still 
not well validated. NfL was identified to be an 
independent biomarker of recurrent ICH for CAA in 
our cohort. It was also related to the baseline disease 
severity, lesion volume, and clinical outcomes at 6 
months. Our  findings well correlated with another 
study of patients with recent small subcortical 
infarcts, which demonstrated baseline NfL level was 
associated with infarct size and the occurrence of new 
lesion at 3 months [21]. Measuring NfL is of great 
help for the risk stratification in CAA-ICH patients, 
especially in those who could not take MRI scan in 
the acute phase of ICH, although the cost is relatively 
expensive. As a biomarker of the axonal injury, 
elevated blood NfL levels are observed in almost all 
neurodegenerative disorders as well as vascular 
conditions [14]. CAA is a SVD disease intermixed 
with the neurodegenerative process, but previous 
studies mostly focused on the pathophysiological 
process of Aβ-triggered vascular damage [8]. Our 
findings demonstrate that the neuroaxonal 
degeneration does prospectively contribute to the 
development of ICH in CAA, emphasizing the 
importance of pathologies other than Aβ. The 
neuroaxonal injury could be a potential therapeutic 
target for CAA-ICH. 
 
Compared to controls, patients with CAA showed 
elevated total tau and decreased Aβ42/Aβ40 levels 
with no differences in the levels of Aβ42 or Aβ40 
itself alone. None of Aβ42, Aβ40 or tau was 
independently predictive of ICH recurrence in CAA. 
Since all the blood samples of patients with CAA 
were collected at the acute phase of ICH, it was hard 
to tell whether CAA or the event of ICH lead to the 
change of levels. The blood Aβ42/Aβ40 ratio might 
eliminate the effect of acute stroke event itself. 
Previous data confirmed that the decreased plasma 
Aβ42/Aβ40 accurately diagnosed brain amyloidosis in 
cognitively normal participants [22] and the decreased 
cerebrospinal fluid (CSF) Aβ42 and Aβ40  
(the Aβ42/Aβ40 was not studied) served as 
biomarkers for diagnosing CAA [6]. Our findings 
raised the possibility that blood Aβ42/Aβ40 might 
help distinguish CAA from controls as blood Aβ 
detected by SIMOA was well correlated with CSF Aβ 
[23]. Blood taken from CAA-ICH more than 6 months 
after the hemorrhagic event or from CAA with 
cognitive decline were needed to confirm its 
diagnostic value. 
 
Our study has several limitations. First, the hospital-
based recruitment from a specific geographical area 
might limit the generalizability of our results, and the 
number of patients with probable CAA-ICH in our 
study was not that large as that of MGH cohort [2]. 
We designed a prospective cohort to demonstrate the 
CAA-ICH recurrence rate and relevant predictors in 
China with 2.4 years’ follow-up. Even in this 
relatively small sample, we were able to determine the 
novel blood biomarker to predict recurrent ICH in 
CAA. Second, we did not collect blood samples from 
patients with other types of ICH as comparisons, so it 
was hard to explore the effect of the 
pathophysiological process of CAA and the acute 
event of ICH on the levels of blood biomarkers. Third, 
serial blood samples were not available to determine 
which timepoint was the best for the prediction of 
clinical outcomes in CAA, since levels of most 
inflammatory factors varied over time after onset. For 
NfL, it increased starting from admission, peaked at 
day 7 and remained elevated till 6 months post 
ischemic stroke, with no differences between that of 
day 1, day 2 and day 3 [24, 25]. We collected blood 
samples between 1-3 days of ICH onset and acute 
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phase blood biomarkers might be of the greatest value 
to evaluate disease severity and prognosis.  
 
In conclusion, acute phase blood NfL is a significant 
biomarker of CAA-ICH recurrence independent of 
total MRI burden of SVD and is associated with 
disease severity and clinical outcome of CAA. Thus, 
NfL is a promising addition to MRI burden of SVD to 
predict CAA-ICH recurrence. 
 
MATERIALS AND METHODS 
 
Study population 
 
We prospectively collected cases with first CAA-ICH 
admitted at Huashan Hospital Fudan University 
(Shanghai, China) from January 2014 to September 
2018 and at First Affiliated Hospital of University of 
Science and Technology of China (Hefei, China) from 
January 2018 to September 2018, and sex- and age-
matched healthy elder adults from participants in 
Shanghai Aging Study during the same period as 
previously reported [26]. For cases with CAA, the 
inclusion criteria included: 1) first spontaneous lobar 
ICH within 48 hours of onset and pathologically or 
clinically diagnosed with probable CAA according to 
the modified Boston criteria [27]; 2) cases survived 
the first 30 days; 3) available blood samples within 24 
hours after admission, CT scan within 24-48 hours 
and MR images including T1, T2, T2 fluid attenuated 
inversion recovery (FLAIR) and susceptibility 
weighted imaging (SWI) within 14 days after the 
event; 4) available follow-up information for mRS at 
six months and recurrent ICH. We personally inquired 
about the detailed medical history and examined the 
patient at baseline. The assessment of pre-existing 
dementia was done at baseline with the short version 
of the Informant Questionnaire on Cognitive Decline 
in the Elderly (IQCODE) [28]. All patients were 
regularly followed-up every six months by phone calls 
or face-to-face interview until the ICH recurrence, 
death or October 2019. ICH recurrence was defined as 
a new symptomatic lobar ICH event confirmed by 
corresponding lesion on CT or SWI scan during 
follow-up period [2]. The current study was approved 
by local ethics committees. The written informed 
consent was provided by the patient or a legally 
responsible relative. 
 
Blood samples and biomarkers measurements 
 
Blood samples were drawn from the peripheral vein of 
each participant and collected in tubes with and 
without EDTA, within 24 hours since admission for 
patients with CAA and during follow-up period for 
healthy elder people. After centrifugation at 3,000rpm 
for 15 minutes, the plasma and serum were kept at 
−80° C until measurement. 
 
All measures were performed blinded to the clinical 
data. Serum NfL and plasma Aβ40, Aβ42 and total tau 
were measured using the SIMOA NF-light assay (Cat 
No: 102258) and Neurology 3-Plex A (Cat No: 101995) 
respectively, per manufacturer instructions (Quanterix, 
MA, US) on a HD-1 platform at GBIO (Hangzhou, 
China) with dilution at 1:4 ratio. All samples were 
duplicated for detection and intra- and inter-assay 
concentration variabilities were <15%. 
 
MRI protocols and imaging analysis 
 
CAA patients and healthy controls were scanned on 
Siemens 3.0T MRI and GE 3.0T scanner separately. 
Imaging included T1-weighted, T2-weighted, FLAIR 
and SWI, and parameters of the sequences were shown 
in Supplementary Materials. 
 
Two experienced raters (Y.W. and Y.X.) blinded to the 
clinical history independently evaluated SVD imaging 
markers according to the STRIVE (STandards for 
ReportIng Vascular changes on nEuroimaging) [29] and 
validated scales. If there was a disagreement a third rater 
(Y.S.) was consulted. CMBs which were not immediately 
adjacent to the lobar ICH were counted on SWI and 
classified into deep and lobar categories [30]. cSS 
presence was defined as hypointense curvilinear signal 
intensity in the superficial layers of the cerebral cortex on 
SWI, away from at least 2 sulci of the hemorrhagic lesion, 
and its extent was rated as focal (less than 3 sulci) or 
disseminated (>3 sulci) distribution on SWI [31]. PVS 
were measured by a 4-point scale (0 = no PVS, 1 = ≤10 
PVS, 2 = 11–20 PVS, 3 = 21–40 PVS, 4 = >40 PVS) in 
the CSO on T2-weighted images [32] and WMH severity 
was evaluated using Fazekas scale on FLAIR [33], both 
from the ICH-free hemisphere in patients with CAA. The 
total MRI burden of SVD was calculated by accumulating 
CMBs number, WMH severity, cSS presence and extent 
and CSO-PVS severity, ranging from 0 to 6 points [16]. 
ICH volume was measured by 1/2*(length*width*height) 
on CT scan. 
 
Statistical analysis 
 
Descriptive statistics included counts with percentages 
[n(%)] and mean ± SD for normally distributed 
continuous variables or median with IQR for non-
normally distributed continuous variables. We 
compared demographic, clinical, imaging characteristics 
and the distribution of blood biomarkers between 
healthy controls and cases with CAA-ICH using one-
way analysis of variance or Mann-Whitney test for 
continuous variables and χ2 test or Fisher exact test for 
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categorical variables. We log-transformed blood 
biomarkers to obtain a normal distribution for further 
analyses of cases with CAA-ICH.  
 
We used univariable and multivariable Cox regression 
analyses with forward selection to calculate HR with 
95% CI and establish the prognostic model for CAA-
ICH recurrence. First, we identified clinical and 
imaging variables associated with CAA-ICH 
recurrence (p<0.05) in univariable analyses and 
variables with known potential clinical significance 
(including age, sex, pre-existing dementia, cSS 
presence and extent, CSO-PVS severity, lobar CMBs 
count, WMH severity and total MRI burden of SVD) 
[1–3, 5] to determine the clinical model (Model 1). 
Then biomarkers of Aβ40, Aβ42, Aβ42/40, total tau 
and NfL were added to build the ‘clinical + biomarker’ 
model (Model 2). The performance of these prognostic 
models was evaluated by discrimination (c-index) and 
calibration (internal bootstrap validation) in R 
software. Comparisons of the models’ c-indexes were 
made using the compareC package. We explored the 
ability of the best biomarker in predicting recurrent 
ICH by a ROC curve and estimates of the area under 
the curve. We also analyzed the Kaplan–Meier plot 
with log-rank test of the predictor above and below the 
upper tertile. Last, we used univariable and 
multivariable regression models to estimate the 
association between the blood biomarker and baseline 
ICH volume, 6-month mRS (with age, baseline NIHSS 
score and total MRI burden of SVD as covariables), 
and baseline NIHSS score (with age, ICH volume and 
total MRI burden of SVD as covariables). Coefficient 
and OR with 95% CI were reported. 
 
Statistical Analyses were performed using STATA 
version 16.0 (StataCorp, Ltd, College Station, TX) and 
R software version 3.1.2 (Institute for Statistics and 
Mathematics, Vienna, VIC, Austria). A two-tailed 
p<0.05 was considered as significant. 
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Aβ: β-amyloid; CAA: cerebral amyloid angiopathy; CI: 
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SUPPLEMENTARY MATERIALS 
 
 
MRI parameters 
 
All patients with CAA were scanned on a Siemens 
MAGNETOM Verio 3.0T MRI system. Parameters of 
the sequences were as follows: T1 MPRAGE (repetition 
time [TR]/echo time [TE] 1780/2.9 ms, in-plane matrix 
512 × 512, slice thickness 1.0 mm), T2 SPACE (TR/TE 
3000/330 ms, in-plane matrix 320 × 320, slice thickness 
2.0 mm), T2 FLAIR (TR/TE 9000/99 ms, in-plane 
matrix 512 × 512, slice thickness 2.0 mm) and SWI 
(TR/TE 28/20 ms, in-plane matrix 350 × 448, slice 
thickness 1.5 mm) sequences. 
For healthy controls, MRIs were obtained by GE 
MR750 discovery 3.0T scanner, including T1 BRAVO 
(TR/TE 8.2/3.2 ms, in-plane matrix 512 × 512, slice 
thickness 1.0 mm), T2 PROPELLER (TR/TE 10400/80 
ms, in-plane matrix 512 × 512, slice thickness 2.0 mm), 
Cor CUBE FLAIR (TR/TE 6000/90 ms, in-plane matrix 
512 × 512, slice thickness 2.0 mm) and SWI (TR/TE 
78/45 ms, in-plane matrix 512 × 512, slice thickness 2.0 
mm) sequences. 
 
